The average P/S ratio for XENE's competitors is 37.66, providing a benchmark for relative valuation. Xenon Pharmaceuticals Inc Corp (XENE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.